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Recently, we identified a GTPase-activating protein for the ADP
ribosylation factor family of small GTP-binding proteins that we
call GIT1. This protein initially was identified as an interacting
partner for the G protein-coupled receptor kinases, and its over-
expression was found to affect signaling and internalization of the
prototypical b2-adrenergic receptor. Here, we report that GIT1
overexpression regulates internalization of numerous, but not all,
G protein-coupled receptors. The specificity of the GIT1 effect is not
related to the type of G protein to which a receptor couples, but
rather to the endocytic route it uses. GIT1 only affects the function
of G protein-coupled receptors that are internalized through the
clathrin-coated pit pathway in a b-arrestin- and dynamin-sensitive
manner. Furthermore, the GIT1 effect is not limited to G protein-
coupled receptors because overexpression of this protein also
affects internalization of the epidermal growth factor receptor.
However, constitutive agonist-independent internalization is not
regulated by GIT1, because transferrin uptake is not affected by
GIT1 overexpression. Thus, GIT1 is a protein involved in regulating
the function of signaling receptors internalized through the clath-
rin pathway and can be used as a diagnostic tool for defining the
endocytic pathway of a receptor.
G protein-coupled receptor function is tightly regulated bynumerous downstream signaling events. Agonist stimula-
tion of a G protein-coupled receptor triggers a conformational
change allowing activation of coupled G proteins through GDP–
GTP exchange (1). This conformational change also promotes
activation of the G protein-coupled receptor kinases (GRKs)
to phosphorylate the activated receptor, allowing binding of
b-arrestin proteins that sterically prevent further coupling to
heterotrimeric G proteins (2, 3). Binding of b-arrestins to
GRK-phosphorylated G protein-coupled receptors also is be-
lieved to initiate receptor sequestration into endosomal recycling
compartments (4). This event appears to be one mechanism by
which activated receptors are dephosphorylated and resensitized
(3, 5, 6). We recently identified a GRK-interacting protein that
we call GIT1 (GRK-interactor 1) and showed that overexpres-
sion of this protein in HEK 293 cells markedly affects signaling
and trafficking of the b2-adrenergic receptor (b2AR) (7). Inter-
estingly, GIT1 contains an active ADP ribosylation factor (ARF)
GTPase-activating protein domain (GAP) at its amino terminus
and binds GRKs through a region located near the carboxyl
terminus. The ability of GIT1 to inhibit b2AR internalization
requires the intact ARF GAP domain, suggesting that GTP–
GDP cycling of ARF proteins may be involved in this process (7).
Further, there appear to be at least three members of the GIT
protein family, GIT1, GIT2yCAT2, and PKL (7–9), which also
interact with the PIXyPAK complex and with paxillin, as well as
PIP3 lipids (R.T.P., unpublished observations; and N. Vitale,
personal communication) (8, 9). The functional consequences of
these interactions for receptor biology still remain to be defined.
In our first report (7), we noted that GIT1 overexpression
inhibited b2AR internalization. Sequestration of cell surface
receptors can occur through different pathways, which differ in
the size and the composition of the proto-vesicle coat (clathrin,
nonclathrin, caveolae, and macropinosome) (10). The most
extensively studied mechanism for receptor-mediated endocy-
tosis occurs by means of the clathrin-coated pits and vesicles
(11). Proteins like the arrestins and dynamins play important
roles in the function of clathrin-coated pits. Arrestins have been
shown to interact with clathrin (12–14), the major protein
component of clathrin-coated pits, as well as with the clathrin
adaptor protein AP-2 (15), and the N-ethylmaleimide-sensitive
fusion protein (NSF) (16). Furthermore, dynamin, a large GT-
Pase, is involved in pinching off of clathrin-coated vesicles from
the plasma membrane (17–22). Moreover, dynamin also has
been localized in caveolae, and its GTPase activity also appears
to be essential for budding of vesicles from these structures
(23, 24).
Although many studies have addressed the precise functions of
proteins that mediate the complex process of clathrin-dependent
internalization, additional factors that are required for this and
other endocytic pathways remain to be defined. In an attempt to
further delineate the role of GIT1 in regulating cell surface
receptor function and trafficking, we examined the role of this
newly appreciated GRK-interacting protein in the internaliza-
tion of a variety of receptors.
Materials and Methods
Materials. Tissue culture media and FBS were obtained from Life
Technologies (Rockville, MD). Isoproterenol, angiotensin II, anti-
Flag M2, and anti-c-myc mAbs, anti-mouse IgG-FITC-conjugated
antibody, and monodansylcadaverine were purchased from Sigma.
Vasoactive intestinal peptide and endothelin-1 were purchased
from Peninsula Laboratories. Mouse anti-hemagglutinin (HA)
12CA5 mAb was obtained from Roche Molecular Biochemicals.
Fluorescein-labeled transferrin and rhodamine-labeled goat anti-
mouse antibodies were from Molecular Probes. Recombinant
epidermal growth factor (EGF) was obtained from Calbiochem.
Anti-human EGF receptor (clone 528) antibody was obtained from
Santa Cruz Biotechnology.
Plasmids. The rat vasoactive intestinal peptide (VIP)1 receptor
(25) was amplified from rat liver cDNA library and subcloned
into the pcDNA1yAmp vector (Invitrogen). The pcDNA1y
Amp-Flag-VIP1 receptor was generated by amplifying the entire
receptor cDNA using an oligonucleotide primer that inserted a
HA signal sequence and Flag epitope (DYKDDDDA) imme-
diately before amino acid 1 of the mature receptor, replacing the
endogenous signal sequence, as described for the b2AR (26).
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The pBK-Flag-A2B was prepared in the same manner from the
corresponding human wild-type receptor cDNA. The pRK5-
HA-M1 and pRK5-HA-M2 muscarinic acetylcholine receptors
were generated by amplifying the receptor cDNAs using oligo-
nucleotide primers that inserted HA signal sequence and HA
epitope (YPYDVPDYA, recognized by the 12CA5 mAb) im-
mediately after the initiator methionine. All constructs were
verified by sequencing. The pBK-Flag-b2AR (7), pBK-GIT1-
Flag (7), pcDNA3-Flag-b1 adrenergic receptor (27), pcDNA3-
HA-m-opioid receptor (28), pcDNA1-Flag-endothelin B recep-
tor (29), and pcDNA1-HA-angiotensin 1A receptor (30) have
been described.
Cell Culture and Transfection. HEK 293 cells were maintained in
MEM supplemented with 10% FBS, 100 unitsyml penicillin G,
and 100 mgyml streptomycin sulfate at 37°C, 5% CO2. Before
transfection, cells were grown to 60–75% confluency. Cells were
transiently transfected overnight in 100-mm dishes (Falcon) with
12 mg of total plasmid DNA using calcium phosphate precipi-
tation (31). After transfection (’16 h), the cells were incubated
with fresh medium and allowed to recover for 8 h before being
reseeded into 12- or 6-well dishes. The generation of the GIT1
stable cell line has been described (7).
Sequestration Assays. Receptor sequestration was determined by
flow cytometry as described (32) using Flag-b2AR, Flag-b1AR,
Flag-VIP1R, Flag A2BR, HA-mOR, Flag-ETB, HA-M1 MR,
HA-M2 MR, HA-AT1AR, and EGFR transiently transfected in
HEK 293 cells or in cells stably overexpressing GIT1. Receptor
sequestration was defined as the fraction of cell surface receptor
of naive cells that was no longer accessible to antibodies outside
the cells after agonist treatment. Baseline fluorescence from
cells transfected with empty vector was subtracted from each
sample. In some experiments, cells were treated with monodan-
sylcadaverine (400 mM) for 30 min before agonist stimulation.
Transferrin Uptake Assay. Transferrin uptake assays were per-
formed as described (33). Briefly, GIT1-Flag and dynamin II
K44A were transfected into COS 7 cells on coverslips using
Lipofectamine (GIBCOyBRL) according to the manufacturer’s
instructions. Forty-eight hours after transfection, cells were
serum-starved for 1 h, labeled for 15 min with 20 mgyml of
fluorescein-labeled transferrin, rinsed, and fixed with 3% para-
formaldehyde for 25 min. The cells then were permeabilized for
5 min with acetone (220°C) and immunostained with anti-Flag
or anti-c-myc antibodies and rhodamine-labeled anti-mouse IgG
secondary antibodies. Digital f luorescence images were acquired
with a Photometrics (Tuscon, AZ) cooled charge-coupled device
mounted on a Zeiss Axiovert 135 epifluorescence microscope.
Data Analysis. The mean and SEM are expressed for values
obtained from the number of separate experiments indicated.
Statistical analysis was performed by a two-way ANOVA fol-
lowed by an unpaired Student’s t test.
Results
We recently demonstrated that GIT1 overexpression in HEK 293
cells leads to a marked reduction in cAMP signaling ability of the
endogenous b2AR along with increased receptor phosphoryla-
tion and reduced agonist-dependent receptor sequestration from
the cell surface (7). We proposed that GIT1 overexpression
inhibits agonist-promoted internalization of the b2AR, which in
turn leads to accumulation of phosphorylated receptors and
reduced signaling capacity. To explore the generality of this
receptor modulatory activity of GIT1, we first examined the
ability of GIT1 overexpression to inhibit the agonist-promoted
internalization of other Gs-coupled receptors. Using transient
expression of Flag or HA epitope-tagged receptor cDNAs, cell
surface receptor number was assessed before and after a 30-min
agonist stimulation (Fig. 1a). Similar to the b2AR, the agonist-
stimulated internalization of the adenosine 2B and b1-adrenergic
receptors was markedly reduced in GIT1-overexpressing cells. In
contrast, the agonist-promoted endocytosis of the VIP1 receptor
was not affected by GIT1 overexpression (Fig. 1a). Furthermore,
stable overexpression of GIT1 reduced cAMP production stim-
ulated by activated endogenously expressed adenosine 2B re-
ceptor, as well as the b2AR, but not by the VIP1 receptor (data
not shown). Taken together, these results provide strong evi-
dence that the inhibitory action of GIT1 overexpression on
receptor function is not specific to the b2AR, but neither is it
common to all Gs-coupled receptors.
We next tested the ability of GIT1 overexpression to alter
endocytosis of receptors coupled to distinct G proteins. We
chose the Gi-coupled m-opioid receptor (mOR) and M2 musca-
rinic receptor (MR), and the Gq-coupled M1 MR, endothelin B
receptor (ETBR), and angiotensin 1A receptor (AT1AR). All five
receptors underwent substantial agonist-promoted sequestra-
tion from the cell surface (Fig. 1 b and c). Agonist-dependent
internalization of the mOR and M1 MR was inhibited by GIT1
overexpression. However, agonist-stimulated endocytosis of the
M2 MR, ETBR, and AT1AR was not affected by GIT1. These
results show that the ability of GIT1 to inhibit receptor endo-
cytosis does not correlate with the type of G protein to which a
Fig. 1. Effect of GIT1 overexpression on internalization of G protein-coupled
receptors. (a) GIT1 overexpression affects the internalization of some Gs-
coupled receptors. Wild-type (WT) and GIT1-overexpressing HEK293 cells
transiently transfected with Flag-tagged b2AR, b1AR, Flag-VIP1R, or A2BR were
incubated with isoproterenol (10 mM), VIP (0.1 mM), or adenosine (10 mM),
respectively, for 30 min before incubation with antibodies as described in
Materials and Methods. (b) Internalization of the Gi-coupled HA-mOR and
HA-M2 MR was assessed in WT and GIT1-overexpressing 293 cells after a
30-min stimulation with etorphine (500 nM) or acetylcholine (ACh) (100 mM),
respectively. (c) Internalization of the Gq-coupled Flag-ETBR, the HA-AT1AR,
and HA-M1 MR was measured in WT and GIT1 overexpressing 293 cells after
a 30-min stimulation with endothelin-1 (0.1 mM), angiotensin II (1 mM), or ACh
(100 mM), respectively. Results are means 6 SEM for 3–6 independent exper-
iments done in duplicate. *, P , 0.001.
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receptor couples, because at least some Gs-, Gi-, and Gq-coupled
receptors can be regulated by GIT1 overexpression, whereas
others are not.
Studies of endocytosis of heptahelical receptors have demon-
strated that several distinct pathways of sequestration from the
cell surface exist. These pathways differ in their sensitivity to
various inhibitors, such as mutants of the b-arrestin1 protein,
b-arrestin 1 V53D, and S412D (14, 34, 35) or a mutant of dynamin
defective in GTP binding (36, 37), dynamin I K44A. Because it
has been demonstrated previously that agonist-promoted se-
questration of the b2AR (12, 38), M1 MR (39, 40), and mOR (28,
41) is inhibited by both b-arrestin and dynamin-dominant neg-
atives and that endocytosis of the M2 MR (42) and AT1AR (38)
is insensitive to these inhibitors, we set out to test whether
sensitivity to GIT1 might be correlated with sensitivity to these
mutants. Thus, we next examined the ability of b-arrestin 1 V53D,
b-arrestin 1 S412D, and dynamin I K44A to affect internalization
of several heptahelical receptors. Of the five receptors affected
by GIT1 overexpression, b2AR, b1AR, A2BR, mOR, and M1
MR, all five also were inhibited by both b-arrestin and dynamin-
dominant negative mutants (Fig. 2). Of the four receptors
unaffected by GIT1, VIP1R, ETBR, M2 MR, and AT1AR, all
were unaffected by the two b-arrestin mutants (Fig. 2). Inter-
estingly, the sequestration of the VIP1R and the ETBR was
substantially inhibited by dynamin 1 K44A, whereas that of the
M2 MR and AT1AR was not (Fig. 2). Thus, sensitivity to GIT1
appears correlated with sensitivity to b-arrestin mutants. How-
ever, sensitivity to dynamin K44A, while occurring for all GIT1-
sensitive receptors, appears to be a feature of a wider class of G
protein-coupled receptors (Table 1).
The sequestration of the b2AR has been reported previously
to use the clathrin-coated pit pathway (4, 12, 43), suggesting that
GIT1 sensitivity may correlate with receptor sequestration by
means of a b-arrestin- and dynamin-sensitive clathrin-coated pit
pathway. As a first step to show that the GIT1-sensitive seques-
tration pathway is indeed the clathrin-coated pit pathway, we
examined receptor sequestration in cells treated with 400 mM
monodansylcadaverine (MDC), which has been reported to
stabilize clathrin cage assembly, thus inhibiting internalization
(44). We tested the effect of MDC treatment on one represen-
tative receptor from each of the sequestration classes: namely,
the b2AR (sensitive to GIT1, and mutants of b-arrestin and
dynamin), the ETBR (sensitive to the dynamin mutant, but not
GIT1 or mutants of b-arrestin), and the AT1AR (insensitive to
GIT1 or mutants of b-arrestin and dynamin). A 30-min pre-
treatment of the cells with MDC substantially inhibited agonist-
promoted sequestration of the b2AR, but was ineffective in
inhibiting agonist-stimulated sequestration of either the ETBR
or AT1AR (Fig. 3). These data suggest that the pattern of
inhibition defined by sensitivity to GIT1, b-arrestin mutants, and
the dynamin mutant may indeed fingerprint the clathrin-
dependent pathway for receptor internalization.
Finally, to distinguish whether GIT1 plays a specific role in
agonist-dependent G protein-coupled receptor internalization
through the clathrin-coated pit pathway or more generally in
clathrin-mediated endocytosis, we examined the effect of GIT1
overexpression on two non-G protein-coupled receptors known
to internalize by means of the clathrin pits: the EGF receptor, a
tyrosine kinase receptor, and the transferrin receptor, a consti-
tutively recycling receptor (45). Signaling receptors, such as
receptor tyrosine kinases and G protein-coupled receptors,
require ligand binding for internalization. Similar to most G
protein-coupled receptors, phosphorylation of the EGF receptor
is necessary for internalization (10, 46, 47). Furthermore, ago-
nist-promoted internalization of G protein-coupled receptors
and tyrosine kinase receptors is associated with the recruitment
of clathrin to the plasma membrane (12, 48–50). First, we
examined the effect of GIT1 on EGF receptor internalization.
Overexpression of GIT1, as well as dynamin K44A, significantly
reduced agonist-promoted sequestration of the EGF receptor
from the cell surface (Fig. 4). These results demonstrate that the
effect of GIT1 on agonist-promoted sequestration of receptors
is not limited to G protein-coupled receptors.
Secondly, we examined whether GIT1 overexpression affected
transferrin uptake through the transferrin receptor. This recep-
tor is continually removed from the cell surface through inter-
nalization in clathrin-coated vesicles. However, in contrast to G
protein-coupled receptors and the EGF receptor, recruitment of
this receptor to the pits and its subsequent internalization does
not require occupancy of the receptor by transferrin. Immuno-
fluorescence microscopy was used to assess changes in the
transferrin accumulation by measuring FITC staining in cells
overexpressing GIT1 or dynamin II K44A. Fig. 5a shows a
representative field of COS 7 cells overexpressing GIT1-Flag
Fig. 2. Effect of b-arrestin and dynamin mutants on agonist-mediated
internalization of G protein-coupled receptors. Sensitivity to b-arrestin 1
(barr) V53D, b-arrestin 1 S412D, and dynamin (dyn) K44A is shown after a 30-min
agonist stimulation. (a) Effect of dominant-negative mutants on internaliza-
tion of Gs-coupled receptors. The Flag-b2AR and Flag-b1AR were stimulated by
isoproterenol (10 mM), the Flag-VIP1R was stimulated by VIP (0.1 mM), and the
Flag-A2BR was stimulated by adenosine (1 mM) for 30 min. (b) The Gi-coupled
HA-mOR and HA-M2 MR were stimulated with etorphine (500 nM) or acetyl-
choline (ACh) (100 mM) for 30 min. (c) Effect of dominant-negative mutants on
internalization of Gq-coupled receptors. The Flag-ETBR was stimulated with
endothelin-1 (0.1 mM), the HA-AT1AR was stimulated with angiotensin II (0.1
mM), and the HA-M2 MR was stimulated with ACh (100 mM). Data represent
the means 6 SEM of 3–5 independent experiments. *, P , 0.01; **, P , 0.001.
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(Upper) or dynamin II K44A-c-myc (Lower) identified by immu-
nostaining (Left). The arrows point to cells overexpressing
GIT1-Flag (Upper) and dynamin II K44A (Lower), whereas the
arrowheads point to the nontransfected cells. These cells were
incubated in the presence of FITC-transferrin for 15 min. The
right panels show FITC-transferrin staining of the same fields
presented in the left panels. As illustrated in the Upper Left, the
GIT1-Flag overexpressing cell (arrow) shows the same FITC-
transferrin internalization (Right) as adjacent cells not overex-
pressing GIT1 (arrowhead). The transferrin appears in both cell
types as speckling within endosomal compartments of the cy-
tosol. In contrast, dynamin II K44A-overexpressing cells (Lower
Left; arrows) show a marked decrease in FITC-transferrin
uptake seen as a decrease in cytosolic localization (Lower Right;
arrows). These results are quantitatively represented in Fig. 5b,
where GIT1-Flag overexpression does not affect FITC-
transferrin uptake, whereas dynamin-dominant negative protein
overexpression markedly inhibits uptake. These results show that
constitutive internalization through clathrin-coated pits is not
affected by GIT1. Thus, the locus of GIT1 action appears to be
consistent with an inhibition of agonist-activated receptor re-
cruitment to or internalization by means of the clathrin-coated
pits, rather than an inhibition of clathrin-coated pit formation
andyor internalization in general.
Discussion
In the present work, we demonstrate that GIT1 is involved in
signaling and trafficking of G protein-coupled receptors that are
internalized by means of the clathrin-coated pit pathway, but not
in the regulation of receptors that internalize by means of other
mechanisms. Considerable efforts have been made to define the
sequence of events initiating and leading to the agonist-
stimulated sequestration of G protein-coupled receptors. The
use of dominant negative mutant proteins and biochemical
inhibitors has been very helpful in delineating the role of
numerous proteins in endocytic pathways. For example, recent
studies have revealed an involvement of the b-arrestin and
dynamin proteins for at least some receptors.
In this study, we used two inhibitory mutants of b-arrestin and
one of dynamin to elucidate the internalization pathways used by
several receptor types, some of which are sensitive to GIT1 and
others that are not. We have noted that receptors that sequester
by means of a b-arrestin-sensitive pathway are also sensitive to
GIT1, whereas receptors that sequester by means of a b-arrestin-
insensitive pathway are not sensitive to GIT1. Analysis of a
number of receptor subtypes has allowed us to define three
patterns of sequestration inhibitor sensitivity: (I) internalization
through a GIT1-, b-arrestin-, and dynamin-sensitive pathway
(b2AR, b1AR, mOR, M1 MR), (II) internalization through a
dynamin-sensitive pathway that is insensitive to GIT1 or b-ar-
restin (VIP1R, ETBR), and (III) internalization through a path-
way that is insensitive to GIT1, b-arrestin, or dynamin (AT1AR,
M2 MR) (Table 1).
According to the classification recently proposed by Bun-
emann et al. (51), the GIT1-sensitive pathway (pathway I)
corresponds to the clathrin-coated pit pathway. Our results
suggest that the internalization mechanism sensitive to GIT1 is
indeed the clathrin pathway because the biochemical inhibitor
MDC also blocks endocytosis of the b2AR, a representative of
the class of receptor that is internalized by means of pathway I,
whereas internalization of the ETBR (pathway II) and AT1AR
(pathway III) is not significantly affected. We conclude that the
distinct patterns of inhibitor sensitivity that we have observed
likely correspond to physically distinct cellular processes, al-
though which precise vesicle coats are involved in the nonclath-
rin-mediated processes remains to be defined for each receptor
Fig. 3. Effect of MDC treatment on internalization of the model G protein-
coupled receptors. HEK 293 cells transiently transfected with Flag-b2AR, Flag-
ETBR, or HA-AT1AR were treated with MDC (400 mM) for 30 min before
stimulation with isoproterenol (10 mM), endothelin-1 (0.1 mM), or angiotensin
II (1 mM), respectively. Data are mean 6 SEM of four experiments done in
duplicate. **, P , 0.01.
Fig. 4. Effect of GIT1 overexpression on agonist-promoted internalization of
the EGF receptor. HEK 293 cells and GIT1 stably overexpressing cells were tran-
siently transfected with the EGF receptor. Wild-type cells overexpressing the EGF
receptor were also transiently transfected with dyn K44A. Cells were stimulated
with EGF for 20 min, and EGF receptor internalization was assayed as described
in Materials and Methods. Values represent the mean 6 SEM from five indepen-
dent experiments done in duplicate. *, P , 0.01; **, P , 0.001.
Table 1. Distinct patterns of inhibitor sensitivity of G
protein-coupled receptor internalization pathways
Pathway Receptor
Agonist-
stimulated
internalization
GIT1-
sensitivity
b-arrestin-
mutant
sensitivity
Dynamin-
mutant
sensitivity
I b2AR Yes 1 1 1
I b1AR Yes 1 1 1
I A2BR Yes 1 1 1
I mOR Yes 1 1 1
I M1 MR Yes 1 1 1
II VIP1R Yes 2 2 1
II ETBR Yes 2 2 1
III AT1AR Yes 2 2 2
III M2 MR Yes 2 2 2
Receptors are grouped into four different pathways of internalization (I–III)
according to their sensitivity to overexpression of GIT1 and mutants of b-ar-
restin and dynamin.
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type. We speculate that pathway II is the caveolae pathway
because internalization of receptors in that class is sensitive to a
mutant of dynamin. Dynamin has been shown to localize to
caveolae structures (23, 24), providing further evidence that this
protein may be involved in caveolae-mediated endocytosis.
Interestingly, the endothelin receptors have been shown to
localize to caveolae (52, 53) in different cell types. Thus, it is
possible that they use this pathway of internalization in a
cell-specific manner. The dynamin-independent pathway used by
the AT1AR and M2 MR (pathway III) may require the partici-
pation of yet another type of internalization machinery, the
components of which remain unidentified. However, Zhang et al.
(38) have shown that the AT1AR internalization can be enhanced
by overexpression of b-arrestin 1, suggesting plasticity in the
choice of endocytic pathways used by a receptor.
Interestingly, the role of GIT1 in endocytosis does not
appear to be limited to G protein-coupled receptors but does
appear to be specific for agonist-promoted clathrin-mediated
internalization. Indeed, overexpression of GIT1 affects the
sequestration of a tyrosine kinase receptor (EGF receptor),
but not that of a constitutively recycling receptor (transferrin
receptor), both of which internalize by means of the clathrin-
coated pit pathway. The major difference between agonist-
promoted and constitutive endocytosis is that the adaptor
recognition signal is constitutively accessible in the latter but
cryptic in the former, until agonist binding has occurred. This
model is attractive for the G protein-coupled receptors be-
cause GIT1 binds the GRKs that phosphorylate only activated
G protein-coupled receptors (7). However, neither GIT1 nor
GRKs are known to have any association with the EGF
receptor. The link between activated signaling receptors (G
protein-coupled receptors and tyrosine kinase receptors) and
GIT1 provided by the GRKs or other adaptor proteins may be
important for receptor recruitment to the clathrin-coated pits.
Our results suggest that GIT1 may play a role in targeting
activated receptors to clathrin-coated pits rather than in pit
formation or internalization per se. However, further experi-
mentation needs to be done to address this point.
Further, we previously have shown that the ARF GAP domain
of GIT1 is critical for its ability to reduce endocytosis and
signaling of the b2AR (7), implying that ARF proteins are
important for regulating clathrin-mediated endocytosis of G
protein-coupled receptors. Moreover, a role for ARF6 in the
internalization of the transferrin receptor has been shown pre-
viously (54). It therefore was surprising that GIT1 did not affect
transferrin receptor function. Perhaps, despite overexpression,
GIT1 may require interaction with other signaling proteins for
recruitment to the activated ARF6 pool on the plasma mem-
brane, and is thus unable to alter transferrin receptor cycling.
Moreover, Cao et al. (55) have suggested that distinct subpopu-
lations of clathrin-coated pits are responsible for endocytosis of
the b2AR and the transferrin receptor. Ligand-induced endo-
cytosis is likely to involve components different from those
engaged by a constitutively cycling receptor.
In this study, we have defined the specificity of the GIT1
protein for regulating cell surface receptor internalization.
Whether the effect of GIT1 solely depends on its ARF GAP
activity remains to be defined. However, the study of ARF
regulatory proteins like GIT1 will give us more insight into the
precise role of these proteins in regulating well-defined inter-
nalization pathways such as the clathrin-coated pit endocytic
pathway. GIT1 also provides a useful tool to distinguish the
different routes of internalization used by G protein-coupled
receptors.
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Fig. 5. Effect of GIT1 overexpression on transferrin uptake. (a) Immunoflu-
orescence of COS 7 cells that have been incubated with FITC-transferrin for 15
min. (Left) A representative field of cells transiently transfected with either
GIT1-Flag (Upper) or dyn K44A-c-myc (Lower), identified by staining with
anti-Flag and anti-c-myc antibodies, respectively (Left). (Right) The fluores-
cence signal of cells from the same field shown on the left that have inter-
nalized FITC-transferrin. The arrows point to cells overexpressing GIT1-Flag
(Upper) and dynamin II K44A (Lower), whereas the arrowheads point to the
nontransfected cells. (b) Quantitative assessment of internalized FITC-
transferrin. FITC-transferrin uptake was quantified by assessing the number of
transfected cells (GIT1-Flag or dynamin II K44A) that have internalized FITC-
transferrin. Results are expressed as percent of FITC-transferrin internaliza-
tion. Data are means 6 SEM of three experiments in which 25–40 cells have
been evaluated. *, P , 0.001
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